{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:25:36Z","timestamp":1785583536758,"version":"3.56.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,7]]},"DOI":"10.7759\/cureus.83652","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T12:13:00Z","timestamp":1746619980000},"source":"Crossref","is-referenced-by-count":2,"title":["Development of Seborrheic Keratosis and Human Papillomavirus (HPV) Infection Following Four Months of Fingolimod Treatment in a Patient With Multiple Sclerosis: A Report of a Rare Case"],"prefix":"10.7759","author":[{"given":"Giorgi","family":"Mamardashvili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazibrola","family":"Botchorishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gucha","family":"Kobaidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/157015911796557911","article-title":"Multiple sclerosis: pathogenesis and treatment","volume":"9","author":"Loma I","year":"2011","unstructured":"Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011, 9:409-16. 10.2174\/157015911796557911","journal-title":"Curr Neuropharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-1002-8","article-title":"A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis","volume":"255 Suppl 1","author":"Weiner HL","year":"2008","unstructured":"Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol. 2008, 255 Suppl 1:3-11. 10.1007\/s00415-008-1002-8","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun J","year":"2010","unstructured":"Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010, 33:91-101. 10.1097\/WNF.0b013e3181cbf825","journal-title":"Clin Neuropharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518807088","article-title":"Warts and all: fingolimod and unusual HPV-associated lesions","volume":"25","author":"Triplett J","year":"2019","unstructured":"Triplett J, Kermode AG, Corbett A, Reddel SW. Warts and all: fingolimod and unusual HPV-associated lesions. Mult Scler. 2019, 25:1547-50. 10.1177\/1352458518807088","journal-title":"Mult Scler"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4172\/2329-6887.1000266","article-title":"Two unexpected cases of rosacea during fingolimod therapy","volume":"6","author":"Brusco S","year":"2018","unstructured":"Brusco S, Bertini M, Scavone C, Docimo R, Bisecco A, Capuano A, Gallo A. Two unexpected cases of rosacea during fingolimod therapy. J Pharmacovigil. 2018, 6:4. 10.4172\/2329-6887.1000266","journal-title":"J Pharmacovigil"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-217885","article-title":"Fingolimod (Gilenya) and melanoma","volume":"2016","author":"Robinson CL","year":"2016","unstructured":"Robinson CL, Guo M. Fingolimod (Gilenya) and melanoma. BMJ Case Rep. 2016, 2016:bcr2016217885. 10.1136\/bcr-2016-217885","journal-title":"BMJ Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1352458521991433","article-title":"Human papillomavirus lesions in 16 MS patients treated with fingolimod: outcomes and vaccination","volume":"27","author":"Mhanna E","year":"2021","unstructured":"Mhanna E, Nouchi A, Louapre C, et al.. Human papillomavirus lesions in 16 MS patients treated with fingolimod: outcomes and vaccination. Mult Scler. 2021, 27:1794-8. 10.1177\/1352458521991433","journal-title":"Mult Scler"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22426","article-title":"Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis","volume":"69","author":"Cohen JA","year":"2011","unstructured":"Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011, 69:759-77. 10.1002\/ana.22426","journal-title":"Ann Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0800-8","article-title":"Infections in patients receiving multiple sclerosis disease-modifying therapies","volume":"17","author":"Grebenciucova E","year":"2017","unstructured":"Grebenciucova E, Pruitt A. Infections in patients receiving multiple sclerosis disease-modifying therapies. Curr Neurol Neurosci Rep. 2017, 17:88. 10.1007\/s11910-017-0800-8","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12770","article-title":"Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis","volume":"41","author":"Haebich G","year":"2016","unstructured":"Haebich G, Mughal A, Tofazzal N. Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis. Clin Exp Dermatol. 2016, 41:433-4. 10.1111\/ced.12770","journal-title":"Clin Exp Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101437","article-title":"Skin warts during fingolimod treatment in patients with multiple sclerosis","volume":"36","author":"Jaafar N","year":"2019","unstructured":"Jaafar N, Zeineddine M, Massouh J, Yamout BI. Skin warts during fingolimod treatment in patients with multiple sclerosis. Mult Scler Relat Disord. 2019, 36:101437. 10.1016\/j.msard.2019.101437","journal-title":"Mult Scler Relat Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357918-development-of-seborrheic-keratosis-and-human-papillomavirus-hpv-infection-following-four-months-of-fingolimod-treatment-in-a-patient-with-multiple-sclerosis-a-report-of-a-rare-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T12:13:01Z","timestamp":1746619981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357918-development-of-seborrheic-keratosis-and-human-papillomavirus-hpv-infection-following-four-months-of-fingolimod-treatment-in-a-patient-with-multiple-sclerosis-a-report-of-a-rare-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.83652","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}